XML 153 R80.htm IDEA: XBRL DOCUMENT
v3.22.4

Segmentation of key figures (Details 10) - USD ($) $ in Millions | 12 Months Ended
--- | ---
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 50,545 | $ 51,626 | $ 48,659
Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (2.00%) | 6.00% |
Sandoz |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 9,249 | $ 9,631 | 9,646
Net sales, change in % | (4.00%) | 0.00% |
Sandoz | Change to prior year-end [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales, change in % | (4.00%) | 0.00% |
Sandoz | Retail Generics [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 6,776 | $ 7,092 | 7,244
Net sales, change in % | (4.00%) | (2.00%) |
Sandoz | Biopharmaceuticals [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 2,093 | $ 2,116 | 1,928
Net sales, change in % | (1.00%) | 10.00% |
Sandoz | Anti Infectives [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 380 | $ 423 | 474
Net sales, change in % | (10.00%) | (11.00%) |
Sandoz | Anti Infectives [member] | Anti Infectives sold under Sandoz name [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 777 | $ 707 | 694
Sandoz | Anti Infectives [member] | Total anti-infectives net sales [member] |  |  |
Disclosure of operating segments [line items] |  |  |
Net sales to third parties | $ 1,200 | $ 1,100 | $ 1,200

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table. + References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsLineItems
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdParties
Namespace Prefix: | nvs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | nvs_RevenueFromSaleOfGoodsThirdPartiesChangeInPercent
Namespace Prefix: | nvs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | nvs_ChangeOverPeriodAxis=nvs_PoPYEChangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SegmentsAxis=nvs_SandozMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_RetailGenericsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_BiopharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_FranchiseAxis=nvs_AntiInfectivesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_AntiInfectivesSoldUnderSandozNameMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | nvs_ProductPortfolioAxis=nvs_TotalAntiinfectivesNetSalesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |